Fenghauang (Frank) Zhan, PhD Yogesh Jethava, MD University of Iowa Interview Date: December 11, 2018 Summary What cells cause myeloma and why do patients relapse after treatment? Myeloma stem cells may be part of the answer.  Fenghauang (Frank) Zhan, PhD was recently selected as a Myeloma Crowd Research Initiative (MCRI) award recipient. The goal of the MCRI is to[...]

Ashraf Badros, MD University of Maryland Interview Date: October 3, 2018 Summary African Americans are more than twice as likely to develop multiple myeloma. But they are not getting the longest life possible for a variety of reasons. How can they obtain better outcomes and live longer with multiple myeloma? Dr. Badros shares his insights[...]

Irene Ghobrial, MD Dana Farber Cancer Institute Interview Date: September 20,2018 Summary Dr. Irene Ghobrial shares the new PROMISE study, the biggest myeloma screening study ever run to help prevent the blood cancer from occurring by catching it at an early stage. The PROMISE study is supported by a $10M Stand Up 2 Cancer award.[...]

Maria Chaudhry, MD The Ohio State University, The James Cancer Center  Interview Date: September 13, 2018 Summary A new drug by GlaxoSmithKlein drew attention at last year’s American Society of Hematology (ASH) meeting for multiple myeloma patients. Learn more about this antibody drug conjugate which carries a toxic load directly to myeloma cells using the[...]

Paul Richardson, MD Dana Farber Cancer Institute Interview Date: August 3, 2018 Summary Myeloma research is moving quickly, with more treatment approaches being developed by researchers. Dr. Paul Richardson shares a mid-year myeloma update to catch us up and provides a treatment overview for early precursor condition myeloma and for newly diagnosed and relapsed/refractory patients.[...]

Brian McMahon SparkCures Interview Date: July 30, 2018 Summary Why and when should multiple myeloma patients join clinical trials? Brian McMahon of SparkCures shares three steps patients can take to participate in clinical trials: awareness, understanding and action. SparkCures is a clinical trial finder tool specifically for multiple myeloma patients and can help you find[...]

Muhamed Baljevic, MD University of Nebraska Interview Date: May 28, 2018     Many patients’ myeloma can become resistant to an important class of drugs use for myeloma care – proteasome inhibitors. Most patients (70%) will respond to these drugs as single therapies but some patients can be resistant initially. Researchers at MD Anderson Cancer[...]

Rafael Fonseca, MD Mayo Clinic Scottsdale Interview Date: May 18, 2018 Summary Dr. Rafael Fonseca joins Myeloma Crowd Radio to share a new tool for myeloma patients called HealthTree. HealthTree can help myeloma patients find and understand personally relevant treatment options that can then be taken to their doctor for an informed clinic visit. HealthTree[...]

[...]

[...]